Cowealth Medical China Co.Ltd. - Asset Resilience Ratio
Cowealth Medical China Co.Ltd. (603122) has an Asset Resilience Ratio of 2.25% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Cowealth Medical China Co.Ltd. (603122) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2022)
This chart shows how Cowealth Medical China Co.Ltd.'s Asset Resilience Ratio has changed over time. See 603122 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cowealth Medical China Co.Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603122 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥36.00 Million | 2.25% |
| Total Liquid Assets | CN¥36.00 Million | 2.25% |
Asset Resilience Insights
- Limited Liquidity: Cowealth Medical China Co.Ltd. maintains only 2.25% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cowealth Medical China Co.Ltd. Industry Peers by Asset Resilience Ratio
Compare Cowealth Medical China Co.Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB |
Diagnostics & Research | 13.43% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Check-Cap Ltd.
NASDAQ:MBAI |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Annual Asset Resilience Ratio for Cowealth Medical China Co.Ltd. (2019–2022)
The table below shows the annual Asset Resilience Ratio data for Cowealth Medical China Co.Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.64% | CN¥10.00 Million ≈ $1.46 Million |
CN¥1.56 Billion ≈ $228.14 Million |
-19.09pp |
| 2019-12-31 | 19.73% | CN¥222.99 Million ≈ $32.63 Million |
CN¥1.13 Billion ≈ $165.37 Million |
-- |
About Cowealth Medical China Co.Ltd.
Cowealth Medical China Co.,Ltd. operates as a medical company in China. It offers centralized procurement services for in-vitro diagnostic reagents and consumables; platform for decision-making and analysis, commercialization of achievements in medical science and technology; a multi-channel coaxial time audio video imaging platform; and an AI-assisted system for clinical diagnosis. The company w… Read more